Fly News Breaks for March 11, 2015
IPXL
Mar 11, 2015 | 06:51 EDT
Piper Jaffray upgraded Impax Laboratories to Overweight after its survey of 25 neurologists indicated the company's modified-release form of levodopa/carbidopa for Parkinson�s disease will see "significant success." The firm raised its price target for shares to $49 from $37.
News For IPXL From the Last 2 Days
There are no results for your query IPXL